Lab Data Summit 2026

Attendees check-in, grab breakfast, and connect with peers.

Opening remarks centered on the Prognos Health mission of customer obsession and the foundational role of lab data in driving patient care. Following a brief executive welcome from Sundeep, the focus shifts to the industry reality that 70% of clinical decisions are informed by laboratory results. This introduction establishes the strategic framework for leveraging lab data to enhance commercial success and field force effectiveness throughout the summit.

Real-world lab data sits at the foundation of modern precision medicine, yet not all data is created equal. This session explores the evolving landscape of real-world lab data, addressing current trends and challenges, the distinct value of direct versus aggregated data for precision medicine and AI Driven insights expected to shape the industry.

Pharma has invested billions in data, analytics, and omnichannel capabilities—yet one uncomfortable truth remains: much of it isn’t changing behavior in the field.

Marketers still struggle to prove ROI. And “precision” strategies often add complexity without delivering measurable impact.  So where’s the disconnect?  This session takes a hard look at one of the industry’s most pressing challenges: the growing gap between data sophistication and real-world adoption.

Through the lens of oncology and rare disease, we’ll debate whether current approaches to targeting and engagement are fundamentally misaligned with how decisions actually get made—and what it will take to fix it.  From biomarker-driven insights to field-first design, we’ll explore how to move from pushing more data to delivering intelligence that earns trust, influences behavior, and drives outcomes.

Enjoy coffee and snacks while connecting with peers.

Featuring perspectives from those actively building, deploying, and stress-testing AI across healthcare’s most complex data challenges, this panel cuts through the noise - examining what’s actually working today, where enterprise adoption is stalling, and what it will take to turn lab data into a foundation that AI can genuinely act on.

Join facilitated table topic discussions while enjoying a networking lunch featuring a mix of healthy options and Philadelphia favorites.

Join Lidia Fonseca, Chief Digital and Technology Officer at Pfizer, for a candid fireside chat with Sundeep Bhan, CEO of Prognos Health on what it takes to scale digital, AI, and data-driven transformation across healthcare. From leading digital transformation at Quest Diagnostics and Labcorp to driving enterprise-wide innovation in digital, data and technology at Pfizer, Lidia brings a rare, end-to-end perspective on how technology is reshaping the life sciences value chain.

This conversation will go deep on the convergence of lab data and generative AI, exploring how organizations can shift from simple data collection to predictive clinical intelligence. Discover the strategies defining the next era of patient impact - and the digital infrastructure required to support them.

Achieving a 360-degree view of the patient is the "holy grail" of life sciences, but the reality is often a fragmented landscape of inconsistent identifiers and varying data lineage. As organizations work to connect lab, claims, and EHR data, the challenge shifts from simply accessing data to achieving true interoperability at scale. This panel features the architects of the modern data ecosystem discussing how to move past the friction of siloed datasets, unlock the full value of lab data, and build a comprehensive, trustworthy patient view that is decision-grade and actionable in the real world.

Precision oncology is advancing rapidly as new biomarkers, new technologies, and emerging modalities enable more precise patient identification. However, the challenge today is not simply generating more data - it is turning that data into actionable insights across the healthcare ecosystem. Pharma, diagnostics labs, providers, and data partners must work together to translate complex molecular insights into timely treatment decisions  that will improved patient outcomes. This session will explore how oncology testing is evolving and how pharma and diagnostics labs  can better collaborate to ensure the right patients receive the right therapies at the right time.

Late afternoon coffee and treats.

The era of "growth at all costs" is over. For rare disease innovators, success now depends on precision. This session breaks down how to find the "needle in the haystack" using earlier lab signals and how to ensure those patients actually reach therapy. No bios, no generalities - just the tactics of modern rare disease commercialization. 

Synthesizing the day's critical insights to reinforce the transformative power of real-world lab data in driving innovation and improving patient outcomes.

Held in the W Hotel's heated courtyard; drinks and appetizers provided.